InsidersTradesSigma
Track the Kura Oncology, Inc. share price and the full insider trade history of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Kura Oncology, Inc. has logged 74 insider filings. Market capitalisation: €1.1bn. The latest transaction was disclosed on 24 August 2026 (Cession). Among the most active insiders: Bair Teresa Brophy. Every trade is openly available.
74
Insider Decl.
n/a
Thresholds
€3m
5 ops.
Buy Volume
€997,565
28 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Kura Oncology, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$32.00.
47Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 22,666 of 29,064 companies
32.2
score / 100
Value15
Quality49
FCF yld-6.3%
Earn yld-25%
EV/EBITDA·
ROE-168%
Gross mgn100%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 24 August 2026
Declarations74 total
4,345 shares@ US$11.8903Common StockSEC:0001193125-26-363810:0
100,000 shares@ US$12.39Common StockSEC:0001193125-26-363812:0
Canonical exit: 22 Nov 2026 (T+90)
31,487 shares@ US$12.630.036% mcap62.0% of flowCommon StockSEC:0001193125-26-361184:0
100,000 shares@ US$11.120.12% mcap61.8% of flowCommon StockSEC:0001193125-26-354201:0
Canonical exit: 15 Nov 2026 (T+90)
6,103 shares@ US$6.1551.4% of flowCommon StockSEC:0001193125-26-122938:0
10,000 shares@ US$3.124.9% of flowCommon StockSEC:0001193125-26-116834:0
1,813 shares@ US$8.460714.2% of flowCommon StockSEC:0001193125-26-025304:0
3,655 shares@ US$8.460760.5% of flowCommon StockSEC:0001193125-26-025303:0
2,226 shares@ US$8.460731.0% of flowCommon StockSEC:0001193125-26-025302:0
4,096 shares@ US$8.460713.9% of flowCommon StockSEC:0001193125-26-025301:0
1,311 shares@ US$8.46075.9% of flowCommon StockSEC:0001193125-26-025306:0
4,842 shares@ US$8.460674.3% of flowCommon StockSEC:0001193125-26-025305:0
50,000 shares0Common StockSEC:0001193125-26-004570:0
21,250 shares0Common StockSEC:0001193125-26-004569:0
50,000 shares0Common StockSEC:0001193125-26-004567:0
50,000 shares0Common StockSEC:0001193125-26-004564:0
50,000 shares0Common StockSEC:0001193125-26-004562:0
35,000 shares@ US$4.8095.7% of flowCommon StockSEC:0001193125-25-326948:0
10,000 shares@ US$3.1216.9% of flowCommon StockSEC:0001193125-25-314154:0
48,900 shares0Common StockSEC:0001193125-25-283568:0
24,967 shares0Common StockSEC:0001193125-25-283562:0
48,900 shares0Common StockSEC:0001193125-25-283560:0
182,500 shares0Common StockSEC:0001193125-25-283565:0
48,900 shares0Common StockSEC:0001193125-25-283564:0
82,500 shares0Common StockSEC:0001193125-25-283563:0
25 of 74 declarations
关于 Kura Oncology, Inc.
Kura Oncology, Inc.（股票代码：KURA）是一家在美国纳斯达克市场上市的美国生物制药公司。公司成立于 2014 年，总部位于加利福尼亚州圣迭戈，作为一家专注于精准医疗的临床阶段肿瘤药物开发商而声名鹊起。随着时间的推移，它已从一个纯粹的研发故事发展成为一家拥有获批产品和新兴商业足迹的更成熟的生物技术公司。其总体战略围绕基因定义的癌症亚型、生物标志物驱动的开发和靶向小分子疗法。（[sec.gov](https://www.sec.gov/Archives/edgar/data/0001422143/000119312526092567/kura-20251231.htm?utm_source=openai)） Kura 的核心产品组合旨在抑制癌症信号通路，解决血液恶性肿瘤和实体瘤中尚未满足的重大需求。公司的主要资产是口服 menin 抑制剂 KOMZIFTI™ (ziftomenib)。2025 年 11 月，FDA 批准 ziftomenib 用于治疗携带 NPM1 突变的复发或难治性急性髓系白血病 (AML) 成年患者，Kura 表示该产品正在美国以 KOMZIFTI 品牌销售。该项目是与 Kyowa Kirin 合作开发的，后者也支持商业化，并为该资产增加了外部验证。除了 ziftomenib，Kura 继续推进其法尼基转移酶抑制平台，包括 tipifarnib 和 darlifarnib (KO-2806)，重点关注肿瘤学中的合理组合和耐药机制。（[fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ziftomenib-relapsed-or-refractory-acute-myeloid-leukemia-npm1-mutation?utm_source=openai)） 从竞争角度来看，Kura Oncology 在精准肿瘤学领域占据着一个专业利基市场。其主要优势是专注的科学模型、经过验证的商业资产以及围绕明确的疾病遗传驱动因素构建的管线。尽管如此，公司仍在一个竞争激烈且资本密集型行业中运营。其未来在很大程度上取决于 KOMZIFTI 的吸收、其标签的广度和市场渗透率，以及其剩余管线产生额外后期价值的能力。与许多肿瘤生物技术公司一样，Kura 面临与临床执行、监管后续、商业采纳、报销动态以及来自更大或资本更充足的同行竞争相关的风险。（[ir.kuraoncology.com](https://ir.kuraoncology.com/news-releases/news-release-details/kura-oncology-reports-fourth-quarter-and-full-year-2025?utm_source=openai)） 最近的里程碑对投资者很重要：FDA 在 2025 年年中接受 NDA，2025 年 11 月 FDA 批准，此后不久首次在美国商业销售，以及随后强调上市执行和初步收入指标的公司更新。这些事件标志着 Kura 从开发阶段生物技术公司向拥有获批肿瘤产品和不断增长的美国商业版图的公司迈出了有意义的转变。对于讲法语的投资者来说，关键在于 Kura Oncology 现在是一家在纳斯达克上市的美国癌症生物技术公司，拥有差异化的产品故事，但其估值仍然高度受上市执行和管线进展的影响。（[ir.kuraoncology.com](https://ir.kuraoncology.com/news-releases/news-release-details/kura-oncology-and-kyowa-kirin-announce-fda-acceptance-and?utm_source=openai)）
